In a report released yesterday, Stephen Macleod from BMO Capital reiterated a Buy rating on Jamieson Wellness Inc (JWEL – Research Report), with a price target of C$41.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Stephen Macleod has given his Buy rating due to a combination of factors that highlight Jamieson Wellness Inc’s strong growth potential. The company is well-positioned to achieve its long-term revenue target of over $1 billion, driven primarily by its Jamieson Brands segment across various geographies. This growth is supported by favorable market trends such as an aging population, rising incomes, and an increased focus on health and wellness.
In particular, the U.S. and China markets offer significant growth opportunities, with strategies in place to leverage e-commerce and product innovation to boost sales. Additionally, Jamieson’s valuation appears attractive, trading below the peer average, which further supports the Buy recommendation. The company’s ability to expand its market leadership in Canada and capitalize on international opportunities underpins its robust growth outlook.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a C$40.00 price target.
JWEL’s price has also changed moderately for the past six months – from C$34.460 to C$29.460, which is a -14.51% drop .